Bioengineering Research Group, Nanotechnology and Advanced Materials Department, Materials and Energy Research Center (MERC), Tehran, Iran; Research Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran.
Research Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran.
Int J Biol Macromol. 2020 Sep 15;159:117-128. doi: 10.1016/j.ijbiomac.2020.04.274. Epub 2020 May 5.
The chitosan-based thermosensitive hydrogel is one of the attractive in situ forming drug delivery systems that are suggested for ophthalmic applications. However, the use of this thermogel has been limited by non-transparency, relatively low solubility and prolonged gelation time. In this study, a convenient approach has been reported to develop transparent thermosensitive hydrogel with suitable cytocompatibility and gelation properties for glaucoma treatment. After obtaining the optimum quaternization conditions, the developed in-situ gelling formulation of quaternized chitosan was achieved by mixing sodium hydrogen carbonate with β-glycerophosphate as a gelling agent. The formulation was a solution below or at room temperature and turned to a transparent hydrogel around ocular surface temperature within several minutes. The results of thermal and rheological evaluations demonstrated that adding sodium hydrogen carbonate has a synergic effect in enhancing the thermosensitivity of the hydrogel. Also, the prepared hydrogels based on quaternized chitosan presented obvious porous architectures, good swelling, and degradability. Hemolysis and cytotoxicity evaluations suggested that the developed hydrogels indicated good biocompatibility as a drug carrier. Finally, the in vitro release profile of timolol maleate as an anti-glaucoma model drug showed the initial burst release in the early hours and a steady linear release of drug from the hydrogel over 1 week. The obtained results confirmed that the developed hydrogel can be considered as an efficient drug delivery candidate for glaucoma therapy.
基于壳聚糖的温敏水凝胶是一种有吸引力的原位形成药物传递系统,建议用于眼科应用。然而,这种热凝胶的使用受到非透明性、相对低的溶解度和延长的凝胶化时间的限制。在这项研究中,报道了一种方便的方法来开发具有合适细胞相容性和凝胶化特性的透明温敏水凝胶,用于治疗青光眼。在获得最佳季铵化条件后,通过将碳酸氢钠与β-甘油磷酸混合作为凝胶剂,制备了季铵化壳聚糖的原位凝胶制剂。该制剂在室温下或低于室温下为溶液,在几分钟内可转变为接近眼部表面温度的透明水凝胶。热学和流变学评价结果表明,添加碳酸氢钠对水凝胶的热敏性具有协同作用。此外,基于季铵化壳聚糖的制备水凝胶具有明显的多孔结构、良好的溶胀性和可降解性。溶血和细胞毒性评价表明,所开发的水凝胶作为药物载体具有良好的生物相容性。最后,马来酸噻吗洛尔作为抗青光眼模型药物的体外释放曲线显示,在最初的几个小时内有初始突释,药物在水凝胶中以稳定的线性释放超过 1 周。所得结果证实,所开发的水凝胶可被视为治疗青光眼的有效药物传递候选物。